卢夫特韦
卢夫特韦(英语:Lufotrelvir、PF-07304814)是辉瑞公司开发的一种抗病毒药物,可作为3CL蛋白酶抑制剂。[1]它是一种前体药物,其磷酸基团在体内被裂解以产生活性剂PF-00835231。[2]卢夫特韦正在用于治疗COVID-19的人体临床试验中,并显示出对COVID-19的良好活性,包括几种变异株,但与相关药物奈玛特韦不同,它没有口服活性,必须通过静脉注射给药,因此一直总体而言,临床开发中不太受欢迎的候选者。[3][4][5]
法律規範狀態 | |
---|---|
法律規範 |
|
识别 | |
| |
CAS号 | 2468015-78-1 |
PubChem CID | |
DrugBank | |
UNII | |
KEGG | |
ChEBI | |
化学 | |
化学式 | C24H33N4O9P |
摩尔质量 | 552.52 g·mol−1 |
3D模型(JSmol) | |
| |
|
参考文献
- Hoffman RL, Kania RS, Brothers MA, Davies JF, Ferre RA, Gajiwala KS, et al. . Journal of Medicinal Chemistry. November 2020, 63 (21): 12725–12747. PMC 7571312 . PMID 33054210. doi:10.1021/acs.jmedchem.0c01063.
- Boras, Britton; Jones, Rhys M.; Anson, Brandon J.; Arenson, Dan; Aschenbrenner, Lisa; Bakowski, Malina A.; Beutler, Nathan; Binder, Joseph; Chen, Emily; Eng, Heather; Hammond, Holly. . Nature Communications. 2021-10-18, 12 (1): 6055. Bibcode:2021NatCo..12.6055B. ISSN 2041-1723. PMC 8523698 . PMID 34663813. doi:10.1038/s41467-021-26239-2 (英语).
- de Vries M, Mohamed AS, Prescott RA, Valero-Jimenez AM, Desvignes L, O'Connor R, et al. . Journal of Virology. February 2021, 95 (10). PMC 8139662 . PMID 33622961. doi:10.1128/JVI.01819-20.
- Baig MH, Sharma T, Ahmad I, Abohashrh M, Alam MM, Dong JJ. . Molecules. March 2021, 26 (6): 1678. PMC 8002701 . PMID 33802860. doi:10.3390/molecules26061678 .
- Vandyck K, Deval J. . Current Opinion in Virology. August 2021, 49: 36–40. PMC 8075814 . PMID 34029993. doi:10.1016/j.coviro.2021.04.006.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.